Meeting
2016 Genitourinary Cancers Symposium
Comorbidity and androgen deprivation therapy use in men undergoing high-dose radiation for unfavorable intermediate- and high-risk prostate cancer.
Authors
Michael A Dyer
Harvard Radiation Oncology Program, Boston, MA
Michael A Dyer , Ming-Hui Chen , Michelle H. Braccioforte , Brian Joseph Moran , Anthony V. D'Amico
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 41)
DOI
10.1200/jco.2016.34.2_suppl.41
Abstract #
41
Poster Bd #
C1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Results of a multicenter, randomized, phase 3 trial of trimodality therapy with I-125 brachytherapy, external beam radiation therapy, and long- versus short-term androgen deprivation therapy for localized high-risk prostate cancer (TRIP/TRIGU0907).
First Author: Atsunori Yorozu
Poster
2019 Genitourinary Cancers Symposium
External beam radiation therapy and brachytherapy boost versus radical prostatectomy and adjuvant radiation therapy for high-risk prostate cancer.
First Author: Vinayak Muralidhar
Poster
2018 Genitourinary Cancers Symposium
Opinions on the role of brachytherapy boost in management of high-risk prostate cancer: A survey of North American genitourinary expert radiation oncologists.
First Author: Shearwood McClelland III
Poster
2016 Genitourinary Cancers Symposium
Comparisons of outcomes for patients with high-risk prostate cancer treated with brachytherapy, external beam radiation, or radical prostatectomy.
First Author: Jay P. Ciezki